Results 11 to 20 of about 12,338 (219)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure [PDF]

EBioMedicine, 2015
The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib – exhibiting a low-nanomolar IC50 – suggesting
David S. Pitcher, Kate de Mattos-Shipley, Konstantinos Tzortzis, Holger W. Auner, Anastasios Karadimitris, Maurits F. Kleijnen   +5 more
doaj   +2 more sources

Bortezomib alters sour taste sensitivity in mice

Toxicology Reports, 2017
Chemotherapy-induced taste disorder is one of the critical issues in cancer therapy. Bortezomib, a proteasome inhibitor, is a key agent in multiple myeloma therapy, but it induces a taste disorder.
Akihiro Ohishi, Kentaro Nishida, Karin Miyamoto, Mizuka Imai, Ryoko Nakanishi, Kyoko Kobayashi, Akiko Hayashi, Kazuki Nagasawa   +7 more
doaj   +2 more sources

Effective response with bortezomib retreatment in relapsed multiple myeloma

Swiss Medical Weekly, 2012
Previous studies have shown that retreatment of relapsed/refractory multiple myeloma (MM) with a second course of bortezomib therapy could be effective in heavily pre-treated patients.
Christian Taverna, Jérôme Voegeli, Andreas Trojan, Robert A Olie, Albert von Rohr   +4 more
doaj   +2 more sources

Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

, 2022
We conducted a phase II trial to prospectively evaluate the efficacy and safety of bortezomib-cyclophosphamide-dexamethasone (VCD) induction, autologous stem cell transplantation (ASCT), VCD consolidation, and bortezomib maintenance in transplant ...
Takayuki Ishikawa (12081674), Kayoko Nagata (510494), Akihito Yonezawa (12081683), Yoshihiro Kuwabara (286904), Akifumi Takaori-Kondo (510501), Takeshi Maeda (304955), Toshiyuki Kitano (12081668), Hiromi Kitao (12081698), Masayuki Kobayashi (142755), Shinjiro Tominari (586335), Kouhei Yamashita (510498), Mitsumasa Watanabe (12081680), Junya Kanda (454650), Shinji Yasuno (524104), Masaaki Tsuji (12081671), Kenji Ueshima (524105), Kazunori Imada (428120), Kohsuke Asagoe (12081692), Masaharu Nohgawa (12081677), Toshinori Moriguchi (9638591), Hirokazu Hirata (12081686), Yasunori Ueda (1816504), Mitsuru Itoh (2185678), Nobuyoshi Arima (12081689), Naoyuki Anzai (12081695), Hitoshi Ohno (5023949), Hiroyuki Muranushi (12081665), Takeo Nakayama (388728), Ihhwa Kim (12081701), Kiyomi Kawagishi (12081704)   +29 more
core   +1 more source

642 Repurposing bortezomib for improved treatment of melanoma by exploiting immunogenic cell death

, 2022
Immunogenic cell death (ICD) constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies.
Daignault-Mill, SM, S.M. Daignault-Mill, N.K. Haass, Gabrielli, B, R.J. Ju, B. Gabrielli, Zeng, B, Haass, NK, D. Moi, Spoerri, L, L. Spoerri, Moi, D, R. Dolcetti, Ju, RJ, Dolcetti, R, B. Zeng   +15 more
core   +1 more source

Gabapentin Inhibits Bortezomib-Induced Mechanical Allodynia Through Supraspinal Action in Mice

Journal of Pharmacological Sciences, 2014
Bortezomib, an inhibitor of proteasome holoenzyme, is used to treat relapsed and refractory multiple myeloma. Peripheral neuropathy is a treatment-limiting adverse effect of bortezomib and is very difficult to control.
Ryo Kitamura, Tsugunobu Andoh, Shizuka Mizoguchi, Yukako Saito, Hiroki Takahata, Yasushi Kuraishi   +5 more
doaj   +1 more source

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.

PLoS ONE, 2013
BACH2, a B-cell specific transcription factor, plays a critical role in oxidative stress-mediated apoptosis. Bortezomib (Velcade(TM)) is widely used to treat relapsed mantle cell lymphoma (MCL) patients despite varying clinical outcomes.
Zheng Chen, Eric F Pittman, Jorge Romaguera, Luis Fayad, Michael Wang, Sattva S Neelapu, Peter McLaughlin, Larry Kwak, Nami McCarty   +8 more
doaj   +1 more source

Iron increases the susceptibility of multiple myeloma cells to bortezomib

Haematologica, 2013
Multiple myeloma is a malignant still incurable plasma cell disorder. Pharmacological treatment based on proteasome inhibition has improved patient outcome; however, bortezomib-resistance remains a major clinical problem.
Alessandro Campanella, Paolo Santambrogio, Francesca Fontana, Michela Frenquelli, Simone Cenci, Magda Marcatti, Roberto Sitia, Giovanni Tonon, Clara Camaschella   +8 more
doaj   +1 more source

Repurposing bortezomib for improved treatment of melanoma by exploiting immunogenic cell death

, 2022
Immunogenic cell death (ICD) constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies.
Proctor, M, de Lima, P, Daignault-Mill, SM, Gabrielli, B, Zeng, B, Stehbens, SJ, Haass, N, Spoerri, L, Gunasingh, G, Moi, D, Ju, R, Dolcetti, R, Brooks, J, Steptoe, R   +13 more
core   +1 more source

Bortezomib-induced skin eruption [PDF]

, 2008
Bortezomib (Velcad) is a proteasome inhibitor recently developed and mainly used for the treatment of multiple myeloma. Bortezomib represents a novel class of drugs functioning as proteasome inhibitors. Skin complications of bortezomib treatment are very
Favet, L, Sanchez-Politta, S., Piguet, Vincent, Kerl, K, Dietrich, Pierre-Yves, Piguet, V, Kerl, K., Dietrich, P Y, Sanchez-Politta, S, Favet, Laurence   +9 more
core   +1 more source